CARB-X

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome, and vaccines. Our pipeline strategy is to fund and support projects with diverse approaches and mechanisms of action. The more shots on goal we have, the more likely we are to deliver new treatments and approaches for drug-resistant bacteria. The projects in the CARB-X portfolio are in the early stages of research, and there is always a high risk of failure. But if successful, these projects, hold exciting potential in the fight against the deadliest bacteria. If only one succeeds, we will have made tremendous progress.